Literature DB >> 12544371

Single-blind comparison of venlafaxine and nortriptyline in elderly major depression.

Cristóbal Gastó1, Víctor Navarro, Teodoro Marcos, María J Portella, Mercè Torra, Miquel Rodamilans.   

Abstract

The objective of this single-blind study was to compare the efficacy and safety of venlafaxine extended-release and nortriptyline in elderly patients with moderate to severe major depression. In- and out-patients (N=68) with unipolar major depression were randomized to receive 6-month treatment with either nortriptyline or venlafaxine. Outcomes of the two groups were compared using measures including the Hamilton Depression Rating Scale (HDRS) and the Newcastle Scale. Side effects were assessed with the UKU side-effect rating scale. Of the 34 venlafaxine-treated patients, 22 were remitters, 7 were nonremitters, and 5 dropped out. The intent-to-treat remission rate was 71% (22 of 31). Of the 34 who received nortriptyline, 21 were remitters, 7 were nonremitters, and 6 dropped out. The intent-to-treat remission rate was 70% (21 of 30). These results suggest that the remission rate with a therapeutic plasma level of nortriptyline is similar to the remission rate with a standard dose of venlafaxine in this group of elderly major depressed patients. No significant differences were observed between dropout rates in the two groups, but autonomic side-effects were significantly more frequent for nortriptyline than for venlafaxine. These results confirm the efficacy and safety of venlafaxine extended-release for treating elderly major depression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544371     DOI: 10.1097/00004714-200302000-00004

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  7 in total

1.  Pharmacotherapy for late-life depression.

Authors:  George S Alexopoulos
Journal:  J Clin Psychiatry       Date:  2011-01       Impact factor: 4.384

Review 2.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 3.  Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis.

Authors:  Teerapon Dhippayom; Nathorn Chaiyakunapruk; Thitima Jongchansittho
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

4.  Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI.

Authors:  H P Sigurdsson; G Hefner; N Ben-Omar; A Köstlbacher; K Wenzel-Seifert; C Hiemke; E Haen
Journal:  J Neural Transm (Vienna)       Date:  2014-09-26       Impact factor: 3.575

5.  The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.

Authors:  Michael Bauer; Puvan Tharmanathan; Hans-Peter Volz; Hans-Juergen Moeller; Nick Freemantle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-01-22       Impact factor: 5.270

6.  The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults.

Authors:  Lauren M Behlke; Eric J Lenze; Vy Pham; J Philip Miller; Timothy W Smith; Yasmina Saade; Jordan F Karp; Charles F Reynolds; Daniel M Blumberger; Cristiana Stefan; Benoit H Mulsant
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.118

7.  An open treatment trial of duloxetine in elderly patients with dysthymic disorder.

Authors:  Nancy Kerner; Kristina D'Antonio; Gregory H Pelton; Elianny Salcedo; Jennifer Ferrar; Steven P Roose; Dp Devanand
Journal:  SAGE Open Med       Date:  2014-05-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.